NEA 13 GP, Ltd
CIK 1460751 · last filed 2021-05-21
NEA 13 GP, Ltd is a corporate insider who has filed 19 SEC Form 4 insider transactions across 13 companies since 2012. The most recent filing, for COUR, was dated May 21, 2021. Across all open-market trades the lifetime net is −$68.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.01B across reported positions. The firm reports its address in Baltimore, MD. 79 SEC filings were submitted jointly with NEA Partners 13, Limited Partnership.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.01B
13
19
-$68.82M
Filer Profile
BALTIMORE, MD 21202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COUR | 10%+ Owner | 15,059,911 | $5.38 | $80.95M | $0 | 1 | 2021-05-21 |
| SPT | 10%+ Owner | 3,850,354 | $11.55 | $44.47M | $0 | 1 | 2020-11-17 |
| NET | 10%+ Owner | 19,966,269 | $333.92 | $6.67B | $0 | 2 | 2020-11-13 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 0 | — | — | $13.18M | 2 | 2020-04-03 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 2,256,013 | — | — | $0 | 1 | 2017-11-08 |
| RYTM | 10%+ Owner | 1,432,248 | $102.31 | $146.54M | $28.05M | 1 | 2017-10-10 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2016-09-30 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 406,500 | $1.47 | $597.6K | $30.00M | 1 | 2016-01-12 |
| BOX | 10%+ Owner | 2,091,457 | $35.10 | $73.41M | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 3,994,106 | $8.52 | $34.03M | -$120.62M | 3 | 2014-11-28 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 9,870,705 | — | — | $45.00M | 2 | 2013-06-05 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 2,291,180 | $0.08 | $186.0K | $0 | 1 | 2013-06-05 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$64.43M | 1 | 2012-10-30 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-21 | COUR | Other (J) | −9,107,656 | $0 | EDGAR |
| 2020-11-17 | SPT | Other (J) | −5,000,000 | $0 | EDGAR |
| 2020-11-13 | NET | Mixed | — | $0 | EDGAR |
| 2020-05-21 | NET | Mixed | — | $0 | EDGAR |
| 2020-04-03 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Disp (D) | −36,811,404 | $0 | EDGAR |
| 2017-11-08 | Care.com Inc (CRCM) Delisted | Other (J) | −2,000,000 | $0 | EDGAR |
| 2017-10-10 | RYTM | Mixed | +14,641,734 | $28.05M | EDGAR |
| 2016-10-31 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | +10,470,219 | $13.20M | EDGAR |
| 2016-09-30 | Roka BioScience, Inc. (ROKA) Delisted | Buy (P) | — | $0 | EDGAR |
| 2016-01-12 | Epizyme, Inc. (EPZM) Delisted | Buy (P) | +3,333,333 | $30.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.